NIH AI Restriction
NIH policy NOT-OD-25-132 prohibits the use of AI-generated text in grant applications that is not substantially modified by the applicant. All AI-drafted sections must be thoroughly rewritten in your own words before submission.
View full policyAlzheimer's Drug-Development Program (U01 Clinical Trial Optional)
About This Grant
The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.
Grant Summary
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) is a National Institutes of Health grant providing up to $1.5M for municipality. Applications are due 2027-11-05 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $1.5M
2027-11-05
- 1Confirm your organization is eligible for Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) from National Institutes of Health, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to National Institutes of Health before the deadline.
Search & build free — $99 one-time to unlock the export-ready application pack. No subscription.
Don't want to draft it yourself?
We'll draft the complete application against National Institutes of Health's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional): Frequently Asked Questions
Who is eligible for the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)?
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) is offered by National Institutes of Health and is generally open to municipality. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) provide?
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) provides up to $1.5M per award from National Institutes of Health. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) deadline?
Applications for Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) are due 2027-11-05 (open). Because deadlines can change, verify the date with the funder, National Institutes of Health, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)?
To apply for Alzheimer's Drug-Development Program (U01 Clinical Trial Optional), confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from National Institutes of Health.